InvestSMART

Mesoblast Limited (ASX:MSB)

ALERT: Price-sensitive ASX Announcement for MSB
Current share price for MSB : $2.390 0.38 (18.91%)+
Announcement
Release
30 Jul 2026 10:01AM
Price at Release
$2.010
Full Release
download
Summary
The Quarterly Activities Report and Appendix 4C Cash Flow Report for Mesoblast Limited (ASX:MSB; Nasdaq:MESO) for the quarter ending June 30, 2026, highlights several financial and operational achievements. Mesoblast reported Ryoncil® net revenues of US$36 million for the quarter and US$115 million for the full year post-product launch. The company continues to expand the indications for Ryoncil in children and adults with severe inflammatory diseases. Financially, the net operating cash spend was US$43.8 million for the year. Mesoblast had US$103 million in cash at the end of the quarter, after drawing US$50 million from a five-year facility to settle all maturing debts. The company's strategic initiatives include advancing its FDA-approved product Ryoncil® to adults with SR-aGvHD and exploring additional licenses and trials in related therapeutic areas.
Key Points
  • Ryoncil® net revenue was US$36 million for the quarter.
  • Full-year Ryoncil® revenue was US$115 million.
  • Net operating cash spend was US$43.8 million for the full year.
  • US$103 million of cash held at June 30, 2026.
  • Drew US$50 million from a five-year facility to clear debts.
  • Expanding Ryoncil® use to adults with SR-aGvHD.
  • Achieved target of 300 patients treated in a Phase 3 trial for chronic low back pain.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.